CoFI System for Microvascular Obstruction

Organization
CorFlow Therapeutics AG · Switzerland
Solution Type
Ready Product / Solution
Collaboration
R&D Collaboration, Licensing
CoFI System for Microvascular Obstruction

1. Technology overview

CorFlow Therapeutics AG is a Swiss medtech company at Neuhofstrasse 5A, 6340 Baar (VAT CHE 320.873.257). It develops a device to diagnose microvascular obstruction (MVO) during percutaneous coronary intervention and to act as a treatment platform in the cath lab.

The Controlled Flow Infusion (CoFI) System detects MVO, compared with cardiac MRI as gold standard in STEMI patients, and returns microvascular diagnostic information within minutes. It works through the existing guide catheter and wire access and can deliver pharmaceutical or other agents directly into the vasculature by controlled infusion. The system is investigational and not approved in the United States.

2. Highlighted features & specifications

  • MVO detection: Diagnoses microvascular obstruction during PCI.
  • Fast results: Delivers diagnostic information within minutes.
  • Workflow fit: Uses the existing guide catheter and wire access.
  • Controlled infusion: Delivers pharmaceutical or other agents into the vasculature.
  • Platform use: Designed as a diagnostic and treatment platform for the cath lab.

3. Potential application

Primary PCI for STEMI patients in tertiary cardiology hospitals in Vietnam. Clinical research collaborations on microvascular injury. Cath-lab trials of targeted drug delivery.

4. Benefits

Microvascular diagnostic information within minutes during the PCI procedure. Uses the existing guide catheter and wire access, so it fits the PCI workflow. Controlled infusion can deliver therapeutic agents directly to the affected vasculature. Addresses a complication of heart attack for which the company cites MOCA clinical trials.

6. Other information

Swiss company in Baar (CorFlow Therapeutics AG). Per Startupticker (7 May 2026): Phase 1 of the MOCA II FDA pivotal trial enrolled 19 STEMI patients at eight sites; Phase 2 started at Cardiocentro Ticino; the REVITALISE trial was approved in the UK. The website states the CoFI System is investigational only. Founding year not stated.

CorFlow Therapeutics AG
View organization profile

Not ready to connect yet?

Save this solution and come back when you are ready to talk to the provider

Trusted by Our Partners

TechFest VietnamIOM – UN MigrationGIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)APED – Cục Phát triển doanh nghiệp tư nhân và kinh tế tập thểSIHUB – Startup and Innovation Hub of Ho Chi Minh CityHợp tác Đức (Deutsche Zusammenarbeit)SCE & Investment PromotionStartup Vietnam Foundation (SVF)National Startup Support Center (NSSC)01BoosterQuest VenturesBộ Tài chính (Ministry of Finance)ITPC – HCMC Investment and Trade Promotion CentreJICA – Japan International Cooperation AgencyNational Innovation Center (NIC)UK GovernmentBCG – Boston Consulting GroupHAWEEHeineken VietnamTalentnetMB BankVIREA – Liên chi hội Bất động sản Công nghiệp Việt NamJobTestGlobal Supply Chain Support Fund / Aavishkaar CapitalKDANPSE / JPS – Phúc Sang MinhG-AsiaPacificBlueScopeLPBankUlsan Center for Creative Economy & InnovationĐại học Bách khoa Hà Nội – Trường Điện - Điện tửVINK – Vietnam Innovation Network in KoreaTencent WeStart (Shenzhen)Ulsan CollegeK-StartupFaslinkShinhan Future's LabShinhan SecuritiesShinhan FinanceShinhan BankShinhan Life

Start with the right connection

We make innovation easy to access for every business everywhere. The next deal is you.

Contact Us